Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials

References

• American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2016;39:S1–S109.
   PubMed Web of Science ®Google Scholar
• The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–2222.
   PubMed Web of Science ®Google Scholar
• The Emerging Risk Factors Collaboration. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015:314(1):52–60.
   PubMed Web of Science ®Google Scholar
• American Diabetes A. Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–928.
   PubMed Web of Science ®Google Scholar
• McCullochD. Thiazolidinediones in the treatment of diabetes mellitus. Up To Date. 2017;1757
   Google Scholar
• U.S. Food and Drug Administration. Guidance for industry diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2008.
   Google Scholar
• Zinman B, Wanner C, Lcahin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(5):644–657.
   Google Scholar
• Cefalu, W. T, Kaul, S, Gerstein, H. C, Holman, R. R, Zinman, B, Skyler, J. S, Green, J. B, Buse, J. B, Inzucchi, S. E, Leiter, L. A, Raz, I, Rosenstock, J, Riddle, M. C. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care. 2018;41(1):14–31.
   PubMed Web of Science ®Google Scholar
• Garber, A. J, Abrahamson, M. J, Barzilay, J. I, Blonde, L, Bloomgarden, Z. T, Bush, M. A, Dagogo-Jack, S, DeFronzo, R. A, Einhorn, D, Fonseca, V. A, Garber, J. R, Garvey, W. T, Grunberger, G, Handelsman, Y, Hirsch, I. B, Jellinger, P. S, McGill, J. B, Mechanick, J. I, Rosenblit, P. D, Umpierrez, G. E. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2018 executive summary. Endocr Pract. 2018;24(1):91–120.
   PubMed Web of Science ®Google Scholar
• Gurgle HE, White K, McAdam-Marx C. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. Vasc Health Risk Manag. 2016;12:239–249.
   Google Scholar
• US Food and Drug Administration. FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR);2017 [cited 2017 Sep 22]. Available from: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM558427.pdf
   Google Scholar
• JARDIANCE® (empagliflozin) tablets, for oral use Initial U.S. Approval; 2014, 2016 [cited 2017 Sep 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204629s008lbl.pdf
   Google Scholar
• CDC National Center for Chronic Disease Prevention and Health Promotion. Estimates of diabetes and its burden in the United States. National Diabetes Statistics Report; 2017 [cited 2018 Sep 16]. Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
   Google Scholar
• Cai J, Bookhart B, Pfeifer M, Tiggelaar S, Lefebvre P. The prevalence of primary and secondary cardiovascular disease prevention populations among subjects with type 2 diabetes mellitus in the United States. In American Association of Diabetes Educators (AADE): Indianapolis, Indiana; 2017.
   Google Scholar
• Johnson D, Dohrmann S, Mohadjer L. National Health and Nutrition Examination Survey: Sample Design. National Center for Health Statistics, Vital Heath Stat. 2014;2(162):1–25.
   Google Scholar
• US Bureau of Labor Statistics. Consumer Price Index – All Urban Consumers; 2017 [cited 2017 Jan 17). Available from: https://data.bls.gov/cgi-bin/surveymost?cu
   Google Scholar
• CVD-REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. Circulation. 2017;136(12):249–259.
   Google Scholar
• Bonafede, M. M, Johnson, B. H, Richhariya, A, Gandra, S. R. Medical costs associated with cardiovascular events among high-risk patients with hyperlipidemia. Clinicoecon Outcomes Res. 2015;7:337–345.
   PubMed Web of Science ®Google Scholar
• Ampudia-Blasco, F. J, Romera, I, Arino, B, Gomis, R. Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect? Int J Gen Med, 2017;10:23–26.
   PubMed Web of Science ®Google Scholar
• Shetty, S, Stafkey-Mailey, D, Yue, B, Coutinho, Anna B, Wang, W, Landsman-Blumberg, P, Sander, S, Coleman, C. The direct cost of cardiovascular disease-related death in patients with type 2 diabetes mellitus in a commercially insured population in the United States. AMCP 2016 Nexus, October 3–6. National Harbor MD; 2016.
   Google Scholar
• O'Sullivan, AK, Rubin J, Nyambose J, Kuznik A, Cohen DJ, Thompson D. Cost estimation of cardiovascular disease events in the US. PharmacoEconomics, 2011;29(8): 693–704.
   PubMed Web of Science ®Google Scholar
• Straka, Robert J, Liu, Larry Z, Girase, Prafulla S, DeLorenzo, A, Chapman, R. H. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. Cardiovasc Diabetol. 2009;8(1):53.
   PubMedGoogle Scholar
• Ward, A, Alvarez, P, Vo, L, Martin, S. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). J Med Econ. 2014;17(3):176–183.
   PubMedGoogle Scholar
• Chapman, R. H, Liu, L. Z, Girase, P. G, Straka, R. J. Determining initial and follow-up costs of cardiovascular events in a US managed care population. BMC Cardiovasc Disord. 2011;11:11.
   PubMed Web of Science ®Google Scholar